PNT - Eli Lilly extends Point acquisition expiration to December 1
2023-11-17 07:21:14 ET
More on Eli Lilly, POINT Biopharma Global, etc.
- Eli Lilly: Perfectly Priced Healthcare Giant
- POINT Biopharma Global: Why The Market Believes That A Second Bidder May Emerge
- Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug Franchise
- Eli Lilly said to be eyeing $2B German plant amid GLP-1 shortage (update)
- Point Biopharma gains amid regulatory approval, potential for increased Eli Lilly bid after SPLASH results
For further details see:
Eli Lilly extends Point acquisition expiration to December 1